Granules India Limited
Financial trend (85/100) does the heavy lifting; quality (63/100) is the drag.
Buy zoneGranules India Limited earns a Buy from StocksWizard, with a blended score of 74/100. At ₹868.65 it trades below our blended DCF and relative-multiples fair value of ₹1,024.85, about 18% upside to that estimate — we read it as undervalued by 18%. On 31.6x trailing earnings it sits cheaper than the Healthcare median of about 37.4x. The price is about 4% below its 52-week high of ₹909.3 and 69% above the low of ₹513.53. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 5/9. The average analyst target of ₹786.43 implies about 9% downside across 7 analysts. It clears 10 of 13 investability checks, with durability 63, valuation 68 and momentum 77 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹819.88.
Analyst views
1-year price
EOD · 2026-09-2552-week range
-4.47% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Buy74Piotroski F-score 5/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 13.5%
- Pass: Low debt (D/E < 0.5): 0.30x
- Pass: Positive free cash flow
- Pass: Revenue growth > 10%: 23%
- Pass: Earnings growing: 31%
- Pass: Net margin ≥ 10%: 11.1%
- Pass: Current ratio > 1.5: 1.80
- Pass: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 5.86
- Fail: Piotroski ≥ 7: 5/9
Quarterly results
Annual financials
Shareholding
- Promoter39.3%
- Institutions22.6%
- Public & other38.1%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Financially solid — Altman Z 5.86.
Opportunities
- Earnings growing (31% YoY).
- Revenue growing (23% YoY).
- Trading in our value buy zone versus sector peers.
About Granules India Limited
Granules India Limited manufactures and supplies active pharmaceutical ingredients, pharmaceutical formulation intermediates, and finished dosage forms to domestic and international markets. Its product portfolio includes paracetamol, metformin, guaifenesin, and methocarbamol alongside prescription and over-the-counter medications. The company produces tablets, capsules, oral solutions, suspensions, and powders for oral solutions.
Granules India Limited — frequently asked questions
Is Granules India Limited a buy, hold or sell?
StocksWizard currently rates Granules India Limited (GRANULES) a Buy, based on a blended score of 74/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Granules India Limited's fair value?
Our blended DCF and relative-valuation model estimates Granules India Limited's fair value at about ₹1,024.85, versus a current price of ₹868.65 — roughly 18% upside. On that basis the stock looks undervalued by 18%.
Is Granules India Limited financially healthy?
Granules India Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 5/9.
How has Granules India Limited's share price performed?
Granules India Limited is up 7% over three months, and last traded at ₹868.65. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.